secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-058960
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Pharma to report Q1 2024 results on May 14; conference call at 8:30am ET
-------------------------------------------------------------------------------

- First quarter 2024 financial results to be released before U.S. market open on Tuesday, May 14, 2024.
- Management to host conference call at 8:30 a.m. ET on May 14; registration required for dial-in.
- Webcast and replay archived on www.fennecpharma.com for 30 days.
- PEDMARK received FDA approval in September 2022; PEDMARQSI approved in EU (June 2023) and UK (Oct 2023).
- Company is commercial-stage specialty pharma focused on pediatric platinum-induced ototoxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924058960/0001104659-24-058960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924058960/tm2413869d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer